サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：子宮内膜症治療薬の世界市場 (2017～2027年)：子宮内膜症タイプ・診断法・治療法・薬剤カテゴリー・診断タイプ・流通チャネル・エンドユーザー・地域別の産業規模・シェア・動向・機会・予測
市場調査レポート
商品コード
1152247

子宮内膜症治療薬の世界市場 (2017～2027年)：子宮内膜症タイプ・診断法・治療法・薬剤カテゴリー・診断タイプ・流通チャネル・エンドユーザー・地域別の産業規模・シェア・動向・機会・予測

Endometriosis Therapeutics Market- Global Industry Size, Share, Trends, Opportunity, & Forecast, 2017-2027 Segmented By Endometriosis Type, Diagnostic Method, Treatment Method, Drug Category, Diagnostics Type, Distribution Channel, End-User, Region
出版日: | 発行: TechSci Research | ページ情報: 英文 111 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円

こちらのレポートには、数時間（ご購入金額の10%）分のアナリストへの質問／追加調査サービスが含まれております。

子宮内膜症治療薬の世界市場 (2017～2027年)：子宮内膜症タイプ・診断法・治療法・薬剤カテゴリー・診断タイプ・流通チャネル・エンドユーザー・地域別の産業規模・シェア・動向・機会・予測
出版日: 2022年11月01日
発行: TechSci Research
ページ情報: 英文 111 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 目次
概要

世界の子宮内膜症治療薬の市場は、2027年にかけて大きく成長すると予測されています。

婦人科疾患や慢性疾患の拡大、子宮内膜症に苦しむ人々の増加、高度な子宮内膜症治療のためのR&D活動の進行、ホルモン療法や新薬への需要の高まりなどの要因が同市場の成長を推進しています。

当レポートでは、世界の子宮内膜症治療薬の市場を調査し、市場概要、市場規模および市場シェアの推移・予測、各種区分・地域/主要国別の詳細分析、市場への各種影響因子の分析、競合環境、主要企業のプロファイルなどをまとめています。

目次

第1章 製品概要

第2章 調査手法

第3章 世界の子宮内膜症治療薬市場に対するCOVID-19の影響

第4章 VOC (顧客の声)

第5章 エグゼクティブサマリー

第6章 臨床試験の分析

第7章 世界の子宮内膜症治療薬市場の見通し

  • 市場規模・予測
  • 市場シェア・予測
    • 子宮内膜症タイプ別 (表在性腹膜病変・子宮内膜腫・深部浸潤性子宮内膜症)
    • 診断法別 (超音波・内診・腹腔鏡検査・MRI・その他)
    • 治療法別 (ホルモン療法・疼痛管理)
    • 流通チャネル別 (小売薬局・病院薬局・オンライン薬局)
    • エンドユーザー別 (病院および診療所・外来治療センター・その他)
    • 地域別
    • 企業別
  • 製品市場マップ

第8章 北米の子宮内膜症治療薬市場の見通し

  • 市場規模・予測
  • 市場シェア・予測
    • 子宮内膜症タイプ別
    • 診断法別
    • 治療法別
    • 流通チャネル別
    • エンドユーザー別
    • 国別
  • 国別分析

第9章 欧州の子宮内膜症治療薬市場の見通し

  • 市場規模・予測
  • 市場シェア・予測
    • 子宮内膜症タイプ別
    • 診断法別
    • 治療法別
    • 流通チャネル別
    • エンドユーザー別
    • 国別
  • 国別分析

第10章 アジア太平洋の子宮内膜症治療薬市場の見通し

  • 市場規模・予測
  • 市場シェア・予測
    • 子宮内膜症タイプ別
    • 診断法別
    • 治療法別
    • 流通チャネル別
    • エンドユーザー別
    • 国別
  • 国別分析

第11章 南米の子宮内膜症治療薬市場の見通し

  • 市場規模・予測
  • 市場シェア・予測
    • 子宮内膜症タイプ別
    • 診断法別
    • 治療法別
    • 流通チャネル別
    • エンドユーザー別
    • 国別
  • 国別分析

第12章 中東・アフリカの子宮内膜症治療薬市場の見通し

  • 市場規模・予測
  • 市場シェア・予測
    • 子宮内膜症タイプ別
    • 診断法別
    • 治療法別
    • 流通チャネル別
    • エンドユーザー別
    • 国別
  • 国別分析

第13章 市場力学

  • 促進要因
  • 課題

第14章 市場動向・市場展開

第15章 競合情勢

  • Abbott Laboratories, Inc.
  • AbbVie, Inc.
  • Bayer AG
  • Pfizer, Inc.
  • Ipsen SA
  • Evotec SE
  • Myovant Sciences Ltd.
  • Philogen S.p.A.
  • Astellas Pharma Inc.
  • Orphagen Pharmaceuticals, Inc.

第16章 戦略的提言

目次
Product Code: 12975

The global endometriosis therapeutics market is expected to increase appreciably through 2027. Endometriosis is a disorder characterized by the tissues like the covering of the uterus growing on the outer part of the uterus. It is a type of chronic disease led to serve life-impacting pains during periods, sexual intercourse, urination, chronic pelvic pain, abdominal bloating, nausea, and fatigue. Sometimes extreme levels of these disorders can result in depression, anxiety, and infertility. Across the globe, various initiatives are going to make people, majorly women, aware of the problem; there are many off-label practices due to lack of information. In developing countries, the cost of therapy is creating restrain in growth.

According to WHO, almost 10% of reproductive-age women will be affected by this syndrome or disease globally in 2021. Different government organizations and NGOs are running global campaigns to create Awareness. Launching new advanced products and therapies, Awareness about continuous improvement in patients, and improvement in non-invasive diagnostic methods are one of the major factors responsible for the market. Thus, we can expect a rise in growth and demand in the market share of Endometriosis therapeutics in 2027.

Growing Awareness About the Disease and Treatment in Society

The increasing pervasiveness of gynecological and chronic diseases, an increasing number of people suffering from endometriosis, ongoing R&D activities for advanced endometriosis treatment, and rising demand for hormonal therapies & novel drugs are factors responsible for the growth of the Endometriosis Therapeutics Market. As the population increases, the demand for medical treatment and equipment is increasing in various parts of the world. According to the WHO report, in 2021, almost 190 million reproductive women and girls will be affected by endometriosis worldwide. The above data shows that there is massive potential in the market as the number of potential customers is in the millions and continues its grow as the population increases in developing countries; patients are still not aware of endometriosis and take the wrong drugs and treatment when there are any health problems. Thus, different initiatives and awareness program are going on through social media, Online platforms, newspapers, and other means. Therefore, growing awareness about endometriosis can positively impact the market share.

The large number of women worldwide suffering from endometriosis led to increased demand for treatment. Due to its positive outcome, patients are suggesting the treatment to another patient, and this word of mouth are most impactful in term of awareness. Hence, this factor can positively impact the market share. These increasing demands make the player work for significant technological Advancement in therapeutics and improving treatment. Technological Advancement in segments helps the doctor to treat the patient with minimal surgical cuts on the body, less painful processes, and shorter recovery time. All these efforts make the method more in demand and market share.

Various community, government, and community initiatives are running to uplift women's health. Australia has funded 58 million for improving endometriosis under the national action plan. Janani Shishu Suraksha Yojana, National action plan, Women's health alliance is an example of global initiatives. These policies led to increasing demand for endometriosis therapeutics in the market. All the factors mentioned above are expected to drive the growth of the Endometriosis Therapeutics Market.

Off-Label Medication Practices are Hurdle in Growth

After so many awareness campaigns are running over the world, many people are still not reachable. Forget about the treatment. They are unaware of endometriosis and take treatment for another problem. Apart from this, in poorer countries, therapy costs are costly that restrain the market growth.

Continuous R&D for Advance Drug Technology is Driving Growth

The evolution of methods and drugs due to technological advancement per market requirements is expected to create impressive growth in the Endometriosis Therapeutics Market. Market players are proposing novel transdermal drug delivery technologies such as topical applicators to overcome the side effects of oral contraceptives and improve efficiency as many women sufferings from endometriosis increase the demand for treatment.

In 2022, Myovant science Limited and Pfizer LLC. Is collaborate and continued to jointly commercialize MYFEMBREE. This medicine is expected to help both companies combine their expertise to deliver the drug quickly and gain market size.

In 2022, Astellas Pharma Inc. announced the outcome of the drug, which is clinical trial version Phase 3, "SKYLIGHT 4". It is a non-hormonal composite studied for treating sensible to severe vasomotor symptoms associated with menopause (VMS) which will encourage future regulatory organizing submissions.

Market Segmentation

The global endometriosis therapeutics market is segmented based on endometriosis type, diagnostic method, therapeutic method, distribution channel, and end user type. Based on endometriosis type, market is divided into superficial peritoneal lesion, endometrioma, deeply infiltrating endometriosis therapeutics. Based on diagnostic method, market is divided into ultrasound, pelvic examination, laparoscopy, magnetic resonance imaging, and others. Based on treatment method, market is split into hormonal therapy, and pain management. Based on drug category, market is divided into oral contraceptives, progestins, NSAIDs, GnRH analogues, and others. Based on diagnostics type, market is split into pure medical imaging v/s general laboratory use. Based on distribution channel, market is divided into retail pharmacies, hospital pharmacies, online pharmacies. Based on end user, market is divided into hospitals & clinics, ambulatory care center, and others, by company.

Market Players

The Abbott Laboratories, Inc. ; AbbVie, Inc.; Bayer AG; Pfizer, Inc.; Ipsen SA; Evotec SE; Myovant Sciences Ltd.; Philogen S.p.A.; Astellas Pharma Inc.; Orphagen Pharmaceuticals, Inc. are the major market player operating in the Endometriosis Therapeutics Market.

Report Scope:

In this report, global Endometriosis Therapeutics Market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Endometriosis Therapeutics Market, by endometriosis type:

  • Superficial Peritoneal Lesion
  • Endometrioma
  • Deeply Infiltrating Endometriosis Therapeutics

Endometriosis Therapeutics Market, by diagnostic method:

  • Ultrasound
  • Pelvic Examination
  • Laparoscopy
  • Magnetic Resonance Imaging
  • Others

Endometriosis Therapeutics Market, by treatment method:

  • Hormonal Therapy
  • Pain Management

Endometriosis Therapeutics, by drug category:

  • Oral Contraceptives
  • Progestins
  • NSAIDs
  • GnRH Analogues
  • Others

Endometriosis Therapeutics, by distribution channel:

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

Endometriosis Therapeutics Market, by end user type:

  • Hospitals & Clinics
  • Ambulatory Care Center
  • Others

Medical market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • Europe & CIS
    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Egypt
    • Turkey

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global Endometriosis Therapeutics Market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Impact of COVID-19 on Global Endometriosis Therapeutics Market

4. Voice of Customer

5. Executive Summary

6. Clinical Trial Analysis

7. Global Endometriosis Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Endometriosis Type (Superficial Peritoneal Lesion, Endometrioma, Deeply Infiltrating Endometriosis Therapeutics)
    • 7.2.2. By Diagnostic Method (Ultrasound, Pelvic Examination, Laparoscopy, Magnetic Resonance Imaging, Others)
    • 7.2.3. By Treatment Method (Hormonal Therapy v/s Pain Management)
      • 7.2.3.1. By Drug Category (Oral Contraceptives, Progestins, NSAIDs, GnRH Analogues, Others)
    • 7.2.4. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)
    • 7.2.5. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
    • 7.2.6. By Region
    • 7.2.7. By Company (2021)
  • 7.3. Product Market Map

8. North America Endometriosis Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Endometriosis Type (Superficial Peritoneal Lesion, Endometrioma, Deeply Infiltrating Endometriosis Therapeutics)
    • 8.2.2. By Diagnostic Method (Ultrasound, Pelvic Examination, Laparoscopy, Magnetic Resonance Imaging, Others)
    • 8.2.3. By Treatment Method (Hormonal Therapy v/s Pain Management)
      • 8.2.3.1. By Drug Category (Oral Contraceptives, Progestins, NSAIDs, GnRH Analogues, Others)
    • 8.2.4. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)
    • 8.2.5. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
    • 8.2.6. By Country
  • 8.3. North America: Country Analysis
    • 8.3.1. United States Endometriosis Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Endometriosis Type
        • 8.3.1.2.2. By Diagnostic Method
        • 8.3.1.2.3. By Therapeutic Method
        • 8.3.1.2.4. By Distribution Channel
        • 8.3.1.2.5. By End User
    • 8.3.2. Mexico Endometriosis Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Endometriosis Type
        • 8.3.2.2.2. By Diagnostic Method
        • 8.3.2.2.3. By Therapeutic Method
        • 8.3.2.2.4. By Distribution Channel
        • 8.3.2.2.5. By End User
    • 8.3.3. Canada Endometriosis Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Endometriosis Type
        • 8.3.3.2.2. By Diagnostic Method
        • 8.3.3.2.3. By Therapeutic Method
        • 8.3.3.2.4. By Distribution Channel
        • 8.3.3.2.5. By End User

9. Europe Endometriosis Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Endometriosis Type (Superficial Peritoneal Lesion, Endometrioma, Deeply Infiltrating Endometriosis Therapeutics)
    • 9.2.2. By Diagnostic Method (Ultrasound, Pelvic Examination, Laparoscopy, Magnetic Resonance Imaging, Others)
    • 9.2.3. By Treatment Method (Hormonal Therapy v/s Pain Management)
      • 9.2.3.1. By Drug Category (Oral Contraceptives, Progestins, NSAIDs, GnRH Analogues, Others)
    • 9.2.4. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)
    • 9.2.5. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
    • 9.2.6. By Country
  • 9.3. Europe: Country Analysis
    • 9.3.1. France Endometriosis Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Endometriosis Type
        • 9.3.1.2.2. By Diagnostic Method
        • 9.3.1.2.3. By Therapeutic Method
        • 9.3.1.2.4. By Distribution Channel
        • 9.3.1.2.5. By End User
    • 9.3.2. United Kingdom Endometriosis Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Endometriosis Type
        • 9.3.2.2.2. By Diagnostic Method
        • 9.3.2.2.3. By Therapeutic Method
        • 9.3.2.2.4. By Distribution Channel
        • 9.3.2.2.5. By End User
    • 9.3.3. Italy Endometriosis Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Endometriosis Type
        • 9.3.3.2.2. By Diagnostic Method
        • 9.3.3.2.3. By Therapeutic Method
        • 9.3.3.2.4. By Distribution Channel
        • 9.3.3.2.5. By End User
    • 9.3.4. Germany Endometriosis Therapeutics Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Endometriosis Type
        • 9.3.4.2.2. By Diagnostic Method
        • 9.3.4.2.3. By Therapeutic Method
        • 9.3.4.2.4. By Distribution Channel
        • 9.3.4.2.5. By End User
    • 9.3.5. Spain Endometriosis Therapeutics Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Endometriosis Type
        • 9.3.5.2.2. By Diagnostic Method
        • 9.3.5.2.3. By Therapeutic Method
        • 9.3.5.2.4. By Distribution Channel
        • 9.3.5.2.5. By End User

10. Asia-Pacific Endometriosis Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Endometriosis Type (Superficial Peritoneal Lesion, Endometrioma, Deeply Infiltrating Endometriosis Therapeutics)
    • 10.2.2. By Diagnostic Method (Ultrasound, Pelvic Examination, Laparoscopy, Magnetic Resonance Imaging, Others)
    • 10.2.3. By Treatment Method (Hormonal Therapy v/s Pain Management)
      • 10.2.3.1. By Drug Category (Oral Contraceptives, Progestins, NSAIDs, GnRH Analogues, Others)
    • 10.2.4. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)
    • 10.2.5. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
    • 10.2.6. By Country
  • 10.3. Asia-Pacific: Country Analysis
    • 10.3.1. China Endometriosis Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Endometriosis Type
        • 10.3.1.2.2. By Diagnostic Method
        • 10.3.1.2.3. By Therapeutic Method
        • 10.3.1.2.4. By Distribution Channel
        • 10.3.1.2.5. By End User
    • 10.3.2. India Endometriosis Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Endometriosis Type
        • 10.3.2.2.2. By Diagnostic Method
        • 10.3.2.2.3. By Therapeutic Method
        • 10.3.2.2.4. By Distribution Channel
        • 10.3.2.2.5. By End User
    • 10.3.3. Japan Endometriosis Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Endometriosis Type
        • 10.3.3.2.2. By Diagnostic Method
        • 10.3.3.2.3. By Therapeutic Method
        • 10.3.3.2.4. By Distribution Channel
        • 10.3.3.2.5. By End User
    • 10.3.4. South Korea Endometriosis Therapeutics Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Endometriosis Type
        • 10.3.4.2.2. By Diagnostic Method
        • 10.3.4.2.3. By Therapeutic Method
        • 10.3.4.2.4. By Distribution Channel
        • 10.3.4.2.5. By End User
    • 10.3.5. Australia Endometriosis Therapeutics Market Outlook
      • 10.3.5.1. Market Size & Forecast
        • 10.3.5.1.1. By Value
      • 10.3.5.2. Market Share & Forecast
        • 10.3.5.2.1. By Endometriosis Type
        • 10.3.5.2.2. By Diagnostic Method
        • 10.3.5.2.3. By Therapeutic Method
        • 10.3.5.2.4. By Distribution Channel
        • 10.3.5.2.5. By End User

11. South America Endometriosis Therapeutics Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Endometriosis Type (Superficial Peritoneal Lesion, Endometrioma, Deeply Infiltrating Endometriosis Therapeutics)
    • 11.2.2. By Diagnostic Method (Ultrasound, Pelvic Examination, Laparoscopy, Magnetic Resonance Imaging, Others)
    • 11.2.3. By Treatment Method (Hormonal Therapy v/s Pain Management)
      • 11.2.3.1. By Drug Category (Oral Contraceptives, Progestins, NSAIDs, GnRH Analogues, Others)
    • 11.2.4. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)
    • 11.2.5. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
    • 11.2.6. By Country
  • 11.3. South America: Country Analysis
    • 11.3.1. Brazil Endometriosis Therapeutics Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Endometriosis Type
        • 11.3.1.2.2. By Diagnostic Method
        • 11.3.1.2.3. By Therapeutic Method
        • 11.3.1.2.4. By Distribution Channel
        • 11.3.1.2.5. By End User
    • 11.3.2. Argentina Endometriosis Therapeutics Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Endometriosis Type
        • 11.3.2.2.2. By Diagnostic Method
        • 11.3.2.2.3. By Therapeutic Method
        • 11.3.2.2.4. By Distribution Channel
        • 11.3.2.2.5. By End User
    • 11.3.3. Colombia Endometriosis Therapeutics Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Endometriosis Type
        • 11.3.3.2.2. By Diagnostic Method
        • 11.3.3.2.3. By Therapeutic Method
        • 11.3.3.2.4. By Distribution Channel
        • 11.3.3.2.5. By End User

12. Middle East and Africa Endometriosis Therapeutics Market Outlook

  • 12.1. Market Size & Forecast
    • 12.1.1. By Value
  • 12.2. Market Share & Forecast
    • 12.2.1. By Endometriosis Type (Superficial Peritoneal Lesion, Endometrioma, Deeply Infiltrating Endometriosis Therapeutics)
    • 12.2.2. By Diagnostic Method (Ultrasound, Pelvic Examination, Laparoscopy, Magnetic Resonance Imaging, Others)
    • 12.2.3. By Treatment Method (Hormonal Therapy v/s Pain Management)
      • 12.2.3.1. By Drug Category (Oral Contraceptives, Progestins, NSAIDs, GnRH Analogues, Others)
    • 12.2.4. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)
    • 12.2.5. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
    • 12.2.6. By Country
  • 12.3. MEA: Country Analysis
    • 12.3.1. South Africa Endometriosis Therapeutics Market Outlook
      • 12.3.1.1. Market Size & Forecast
        • 12.3.1.1.1. By Value
      • 12.3.1.2. Market Share & Forecast
        • 12.3.1.2.1. By Endometriosis Type
        • 12.3.1.2.2. By Diagnostic Method
        • 12.3.1.2.3. By Therapeutic Method
        • 12.3.1.2.4. By Distribution Channel
        • 12.3.1.2.5. By End User
    • 12.3.2. UAE Endometriosis Therapeutics Market Outlook
      • 12.3.2.1. Market Size & Forecast
        • 12.3.2.1.1. By Value
      • 12.3.2.2. Market Share & Forecast
        • 12.3.2.2.1. By Endometriosis Type
        • 12.3.2.2.2. By Diagnostic Method
        • 12.3.2.2.3. By Therapeutic Method
        • 12.3.2.2.4. By Distribution Channel
        • 12.3.2.2.5. By End User
    • 12.3.3. Saudi Arabia Endometriosis Therapeutics Market Outlook
      • 12.3.3.1. Market Size & Forecast
        • 12.3.3.1.1. By Value
      • 12.3.3.2. Market Share & Forecast
        • 12.3.3.2.1. By Endometriosis Type
        • 12.3.3.2.2. By Diagnostic Method
        • 12.3.3.2.3. By Therapeutic Method
        • 12.3.3.2.4. By Distribution Channel
        • 12.3.3.2.5. By End User
    • 12.3.4. Egypt Endometriosis Therapeutics Market Outlook
      • 12.3.4.1. Market Size & Forecast
        • 12.3.4.1.1. By Value
      • 12.3.4.2. Market Share & Forecast
        • 12.3.4.2.1. By Endometriosis Type
        • 12.3.4.2.2. By Diagnostic Method
        • 12.3.4.2.3. By Therapeutic Method
        • 12.3.4.2.4. By Distribution Channel
        • 12.3.4.2.5. By End User
    • 12.3.5. Turkey Endometriosis Therapeutics Market Outlook
      • 12.3.5.1. Market Size & Forecast
        • 12.3.5.1.1. By Value
      • 12.3.5.2. Market Share & Forecast
        • 12.3.5.2.1. By Endometriosis Type
        • 12.3.5.2.2. By Diagnostic Method
        • 12.3.5.2.3. By Therapeutic Method
        • 12.3.5.2.4. By Distribution Channel
        • 12.3.5.2.5. By End User

13. Market Dynamics

  • 13.1. Drivers
  • 13.2. Challenges

14. Market Trends & Developments

15. Competitive Landscape

  • 15.1. Abbott Laboratories, Inc.
  • 15.2. AbbVie, Inc.
  • 15.3. Bayer AG
  • 15.4. Pfizer, Inc.
  • 15.5. Ipsen SA
  • 15.6. Evotec SE
  • 15.7. Myovant Sciences Ltd.
  • 15.8. Philogen S.p.A.
  • 15.9. Astellas Pharma Inc.
  • 15.10. Orphagen Pharmaceuticals, Inc.

16. Strategic Recommendations